IUPHAR/BPS Guide to Pharmacology CITE
https://doi.org/10.2218/gtopdb/F325/2025.3

Type X RTKs: HGF (hepatocyte growth factor) receptor family in GtoPdb v.2025.3

Chloe J. Peach[1]

1. University of Nottingham, UK

Abstract

The hepatocyte growth factor (HGF) receptor family - MET and Ron - regulate maturation of the liver in the embryo, as well as having roles in the adult, for example, in the innate immune system. HGF is synthesized as a single gene product, which is post-translationally processed to yield a heterodimer linked by a disulphide bridge. The maturation of HGF is enhanced by a serine protease, HGF activating complex, and inhibited by HGF-inhibitor 1, a serine protease inhibitor. MST1, the ligand of Ron, is two disulphide-linked peptide chains generated by proteolysis of a single gene product.

Contents

This is a citation summary for Type X RTKs: HGF (hepatocyte growth factor) receptor family in the Guide to Pharmacology database (GtoPdb). It exists purely as an adjunct to the database to facilitate the recognition of citations to and from the database by citation analyzers. Readers will almost certainly want to visit the relevant sections of the database which are given here under database links.

GtoPdb is an expert-driven guide to pharmacological targets and the substances that act on them. GtoPdb is a reference work which is most usefully represented as an on-line database. As in any publication this work should be appropriately cited, and the papers it cites should also be recognized. This document provides a citation for the relevant parts of the database, and also provides a reference list for the research cited by those parts. For further details see [13].

Please note that the database version for the citations given in GtoPdb are to the most recent preceding version in which the family or its subfamilies and targets were substantially changed. The links below are to the current version. If you need to consult the cited version, rather than the most recent version, please contact the GtoPdb curators.

Database links

Type X RTKs: HGF (hepatocyte growth factor) receptor family
https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=325

Receptors

MET(MET proto-oncogene, receptor tyrosine kinase)
https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1815

Ron(macrophage stimulating 1 receptor)
https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1816

References

1. Adams JL, Smothers J, Srinivasan R and Hoos A. (2015) Big opportunities for small molecules in immuno-oncology. *Nat Rev Drug Discov* **14**: 603-22 [PMID:26228631]
2. Ai J, Chen Y, Peng X, Ji Y, Xi Y, Shen Y, Yang X, Su Y, Sun Y and Gao Y *et al.*. (2018) Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models. *Mol Cancer Ther* **17**: 751-762 [PMID:29237805]
3. Anastassiadis T, Deacon SW, Devarajan K, Ma H and Peterson JR. (2011) Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. *Nat Biotechnol* **29**: 1039-45 [PMID:22037377]

4. Arena S, Pisacane A, Mazzone M, Comoglio PM and Bardelli A. (2007) Genetic targeting of the kinase activity of the Met receptor in cancer cells. *Proc Natl Acad Sci USA* **104**: 11412-7 [PMID:17595299]
5. Bannen LC, Bui M, Jiang F, Tso K, Wang Y and Xu W. (2019) Compounds for the treatment of kinase-dependent disorders Patent number: WO2019148044A1. Assignee: Exelixis, Inc.. Priority date: 26/01/2018. Publication date: 01/08/2019.
6. Bellon SF, Kaplan-Lefko P, Yang Y, Zhang Y, Moriguchi J, Rex K, Johnson CW, Rose PE, Long AM and O'Connor AB *et al.*. (2008) c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. *J Biol Chem* **283**: 2675-83 [PMID:18055465]
7. Bierne H and Cossart P. (2002) InlB, a surface protein of Listeria monocytogenes that behaves as an invasin and a growth factor. *J Cell Sci* **115**: 3357-67 [PMID:12154067]
8. Bladt F, Faden B, Friese-Hamim M, Knuehl C, Wilm C, Fittschen C, Grädler U, Meyring M, Dorsch D and Jaehrling F *et al.*. (2013) EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors. *Clin Cancer Res* **19**: 2941-51 [PMID:23553846]
9. Bode CM, Boezio AA, Albrecht BK, Bellon SF, Berry L, Broome MA, Choquette D, Dussault I, Lewis RT and Lin MH *et al.*. (2012) Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors. *Bioorg Med Chem Lett* **22**: 4089-93 [PMID:22595176]
10. Boezio AA, Berry L, Albrecht BK, Bauer D, Bellon SF, Bode C, Chen A, Choquette D, Dussault I and Fang M *et al.*. (2009) Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors. *Bioorg Med Chem Lett* **19**: 6307-12 [PMID:19819693]
11. Bromberg JS, Weir MR, Gaber AO, Yamin MA, Goldberg ID, Mayne TJ, Cal W and Cooper M. (2021) Renal Function Improvement Following ANG-3777 Treatment in Patients at High Risk for Delayed Graft Function After Kidney Transplantation. *Transplantation* **105**: 443-450 [PMID:32265417]
12. Buchanan SG, Hendle J, Lee PS, Smith CR, Bounaud PY, Jessen KA, Tang CM, Huser NH, Felce JD and Froning KJ *et al.*. (2009) SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. *Mol Cancer Ther* **8**: 3181-90 [PMID:19934279]
13. Buneman P, Christie G, Davies JA, Dimitrellou R, Harding SD, Pawson AJ, Sharman JL and Wu Y. (2020) Why data citation isn't working, and what to do about it *Database* **2020** [PMID:32367113]
14. Burggraaf J, Kamerling IM, Gordon PB, Schrier L, de Kam ML, Kales AJ, Bendiksen R, Indrevoll B, Bjerke RM and Moestue SA *et al.*. (2015) Detection of colorectal polyps in humans using an intravenously administered fluorescent peptide targeted against c-Met. *Nat Med* **21**: 955-61 [PMID:26168295]
15. Chao KL, Tsai IW, Chen C and Herzberg O. (2012) Crystal structure of the Sema-PSI extracellular domain of human RON receptor tyrosine kinase. *PLoS ONE* **7**: e41912 [PMID:22848655]
16. Chen GP. (2012) Compounds As c-Met Kinase Inhibitors Patent number: US20120123126A1. Assignee: Chen GP. Priority date: 08/09/2011. Publication date: 17/05/2012.
17. Cho SY, Lee BH, Jung H, Yun CS, Ha JD, Kim HR, Chae CH, Lee JH, Seo HW and Oh KS. (2013) Design and synthesis of novel 3-(benzo[d]oxazol-2-yl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine derivatives as selective G-protein-coupled receptor kinase-2 and -5 inhibitors. *Bioorg Med Chem Lett* **23**: 6711-6 [PMID:24210504]
18. Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, Chen J, Wang X, Ruslim L and Blake R *et al.*. (2003) A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. *Cancer Res* **63**: 7345-55 [PMID:14612533]
19. Claridge S, Raeppel F, Granger MC, Bernstein N, Saavedra O, Zhan L, Llewellyn D, Wahhab A, Deziel R and Rahil J *et al.*. (2008) Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. *Bioorg Med Chem Lett* **18**: 2793-8 [PMID:18434145]
20. Cui JJ, McTigue M, Nambu M, Tran-Dubé M, Pairish M, Shen H, Jia L, Cheng H, Hoffman J and Le P *et al.*. (2012) Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer. *J Med Chem* **55**: 8091-109 [PMID:22924734]
21. Cui JJ, Rogers EW, Ung J, Whitten J, Zhai D, Deng W, Zhang X, Huang Z, Liu J and Zhang H. (2019) Macrocyclic compounds and uses thereof Patent number: WO2019023417A1. Assignee: Tp Therapeutics, Inc.. Priority date: 28/07/2017. Publication date: 31/01/2019.
22. Cui JJ, Tran-Dubé M, Shen H, Nambu M, Kung PP, Pairish M, Jia L, Meng J, Funk L and Botrous I *et al.*. (2011) Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). *J Med Chem* **54**: 6342-63 [PMID:21812414]

23. Davies J, Liu L, Lu J, Vaillancourt PE, Wortinger MA and Zeng W. c-Met antibodies. Patent number: US8217148. Assignee: Eli Lilly And Company. Priority date: 21/11/2008. Publication date: 10/07/2012.
24. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, Hocker M, Treiber DK and Zarrinkar PP. (2011) Comprehensive analysis of kinase inhibitor selectivity. *Nat Biotechnol* **29**: 1046-51 [PMID:22037378]
25. Dorsch D, Schadt O, Stieber F, Meyring M, Grädler U, Bladt F, Friese-Hamim M, Knühl C, Pehl U and Blaukat A. (2015) Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors. *Bioorg Med Chem Lett* **25**: 1597-602 [PMID:25736998]
26. Flynn DL, Kaufman MD and Smith BD. (2016) Inhibition of tumor cell interactions with the microenvironment resulting in a reduction in tumor growth and disease progression Patent number: WO2016061231. Assignee: Deciphera Pharmaceuticals, Llc. Priority date: 14/10/2014. Publication date: 21/04/2016.
27. Fujita H, Miyadera K, Kato M, Fujioka Y, Ochiiwa H, Huang J, Ito K, Aoyagi Y, Takenaka T and Suzuki T *et al*.. (2013) The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile. *Mol Cancer Ther* **12**: 2685-96 [PMID:24140932]
28. Gao Y, Davies SP, Augustin M, Woodward A, Patel UA, Kovelman R and Harvey KJ. (2013) A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. *Biochem J* **451**: 313-28 [PMID:23398362]
29. Hart AC, Abell L, Guo J, Mertzman ME, Padmanabha R, Macor JE, Chaudhry C, Lu H, O'Malley K and Shaw PJ *et al*.. (2019) Identification of RIPK3 Type II Inhibitors Using High-Throughput Mechanistic Studies in Hit Triage *ACS Med Chem Lett*
30. Hu H, Mu Q, Bao Z, Chen Y, Liu Y, Chen J, Wang K, Wang Z, Nam Y and Jiang B *et al*.. (2018) Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor. *Cell* **175**: 1665-1678.e18 [PMID:30343896]
31. Huang A, Schwall R and Yansura D. (2005) Monovalent antibody fragments useful as therapeutics Patent number: US20050227324 A1. Assignee: Genentech, Inc.. Priority date: 19/12/2003. Publication date: 13/10/2005.
32. Jarantow SW, Bushey BS, Pardinas JR, Boakye K, Lacy ER, Sanders R, Sepulveda MA, Moores SL and Chiu ML. (2015) Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor × c-MET Bispecific Antibody. *J Biol Chem* **290**: 24689-704 [PMID:26260789]
33. Jeong H-j, Ha JD, Cho S-y, Kim H-r, Kwangho L, Jungok L, Choi CW and Park J. (2015) Novel triazolopyrazine derivative and use thereof Patent number: WO2015046653A1. Assignee: Korea Research Institute of Chemical Technology, Handok Co., Ltd.. Priority date: 30/09/2013. Publication date: 02/04/2015.
34. Jia H, Dai G, Weng J, Zhang Z, Wang Q, Zhou F, Jiao L, Cui Y, Ren Y and Fan S *et al*.. (2014) Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for treatment of cancer. *J Med Chem* **57**: 7577-89 [PMID:25148209]
35. Kinoshita K, Asoh K, Furuichi N, Ito T, Kawada H, Hara S, Ohwada J, Miyagi T, Kobayashi T and Takanashi K *et al*.. (2012) Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802). *Bioorg Med Chem* **20**: 1271-80 [PMID:22225917]
36. Kong-Beltran M and Wickramasinghe DM. (2009) Methods and compositions for modulating hyperstabilized c-met. Patent number: US7615529 B2. Assignee: Genentech, Inc.. Priority date: 05/01/2016. Publication date: 10/11/2009.
37. Li S, Huang Q, Liu Y, Zhang X, Liu S, He C and Gong P. (2013) Design, synthesis and antitumour activity of bisquinoline derivatives connected by 4-oxy-3-fluoroaniline moiety. *Eur J Med Chem* **64**: 62-73 [PMID:23644189]
38. Liu X, Wang Q, Yang G, Marando C, Koblish HK, Hall LM, Fridman JS, Behshad E, Wynn R and Li Y *et al*.. (2011) A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3. *Clin Cancer Res* **17**: 7127-38 [PMID:21918175]
39. Lovly CM, Heuckmann JM, de Stanchina E, Chen H, Thomas RK, Liang C and Pao W. (2011) Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. *Cancer Res* **71**: 4920-31 [PMID:21613408]
40. Lu T, Alexander R, Connors RW, Cummings MD, Galemmo RA, Hufnagel HR, Johnson DL, Khalil E, Leonard KA and Markotan TP *et al*.. (2007) Triazolopyridazines as tyrosine kinase modulators Patent number: WO2007075567A1. Assignee: Janssen Pharmaceutica, N.V.. Priority date: 21/12/2005. Publication date: 05/07/2007.
41. Milkiewicz KL, Aimone LD, Albom MS, Angeles TS, Chang H, Grobelny JV, Husten J, Losardo C, Miknyoczki S and Murthy S *et al*.. (2011) Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group.

Bioorg Med Chem **19**: 6274-84 [PMID:21967808]
42. Munshi N, Jeay S, Li Y, Chen CR, France DS, Ashwell MA, Hill J, Moussa MM, Leggett DS and Li CJ. (2010) ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. *Mol Cancer Ther* **9**: 1544-53 [PMID:20484018]
43. Musumeci F, Radi M, Brullo C and Schenone S. (2012) Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors. *J Med Chem* **55**: 10797-822 [PMID:23098265]
44. Nakagawa T, Tohyama O, Yamaguchi A, Matsushima T, Takahashi K, Funasaka S, Shirotori S, Asada M and Obaishi H. (2010) E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models. *Cancer Sci* **101**: 210-5 [PMID:19832844]
45. Ouyang XS, Grandinetti KB, Boren M, Chakravorty S, Chopade S, Jiang P, Kanouni T, Koudriakova T, Makwana O and Pack SK *et al.*. (2025) Discovery of KIN-8741, a Highly Selective Type IIb c-Met Kinase Inhibitor with Broad Mutation Coverage and Quality Drug-Like Properties for the Treatment of Cancer. *J Med Chem* **68**: 10648-10662 [PMID:40459881]
46. Pan BS, Chan GK, Chenard M, Chi A, Davis LJ, Deshmukh SV, Gibbs JB, Gil S, Hang G and Hatch H *et al.*. (2010) MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. *Cancer Res* **70**: 1524-33 [PMID:20145145]
47. Patwardhan PP, Ivy KS, Musi E, de Stanchina E and Schwartz GK. (2016) Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma. *Oncotarget* **7**: 4093-109 [PMID:26675259]
48. Puthiyakunnon S, He X, Boddu S, Huang SH and Cao H. (2017) C-Met Inhibitors are Potential Novel Therapeutic Agents Against Listeria monocytogenes Infection Through Blocking the Bacteria Entry into Nonphagocytic Cells. *Curr Top Med Chem* **17**: 278-289 [PMID:27572078]
49. Qi B, Yang Y, Gong G, He H, Yue X, Xu X, Hu Y, Li J, Chen T and Wan X *et al.*. (2019) Discovery of N^1-(4-((7-(3-(4-ethylpiperazin-1-yl)propoxy)-6-methoxyquinolin-4-yl)oxy)-3,5-difluorophenyl)-N^3-(2-(2,6-difluorophenyl)-4-oxothiazolidin-3-yl)urea as a multi-tyrosine kinase inhibitor for drug-sensitive and drug-resistant cancers treatment. *Eur J Med Chem* **163**: 10-27 [PMID:30503936]
50. Sattler M, Pride YB, Ma P, Gramlich JL, Chu SC, Quinnan LA, Shirazian S, Liang C, Podar K and Christensen JG *et al.*. (2003) A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. *Cancer Res* **63**: 5462-9 [PMID:14500382]
51. Schiering N, Knapp S, Marconi M, Flocco MM, Cui J, Perego R, Rusconi L and Cristiani C. (2003) Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a. *Proc Natl Acad Sci USA* **100**: 12654-9 [PMID:14559966]
52. Schlapbach A, Feifel R, Hawtin S, Heng R, Koch G, Moebitz H, Revesz L, Scheufler C, Velcicky J and Waelchli R *et al.*. (2008) Pyrrolo-pyrimidones: a novel class of MK2 inhibitors with potent cellular activity. *Bioorg Med Chem Lett* **18**: 6142-6 [PMID:18945615]
53. Schroeder GM, An Y, Cai ZW, Chen XT, Clark C, Cornelius LA, Dai J, Gullo-Brown J, Gupta A and Henley B *et al.*. (2009) Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily. *J Med Chem* **52**: 1251-4 [PMID:19260711]
54. Shen Y, Xie Q, Norberg M, Sausville E, Vande Woude G and Wenkert D. (2005) Geldanamycin derivative inhibition of HGF/SF-mediated Met tyrosine kinase receptor-dependent urokinase-plasminogen activation. *Bioorg Med Chem* **13**: 4960-71 [PMID:15978816]
55. Slavish PJ, Price JE, Jiang Q, Cui X, Morris SW and Webb TR. (2011) Synthesis of an aryloxy oxo pyrimidinone library that displays ALK-selective inhibition. *Bioorg Med Chem Lett* **21**: 4592-6 [PMID:21708465]
56. Wang C, Li J, Qu L, Tang X, Song X, Yang F, Chen X, Lin Q, Lin W and Zhou Y *et al.*. (2022) Discovery of D6808, a Highly Selective and Potent Macrocyclic c-Met Inhibitor for Gastric Cancer Harboring *MET* Gene Alteration Treatment. *J Med Chem* **65**: 15140-15164 [PMID:36355693]
57. Wang J, Anderson MG, Oleksijew A, Vaidya KS, Boghaert ER, Tucker L, Zhang Q, Han EK, Palma JP and Naumovski L *et al.*. (2017) ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both *MET*-Amplified and c-Met-Overexpressing Tumors, Irrespective of *MET* Pathway Dependence. *Clin Cancer Res* **23**: 992-1000 [PMID:27573171]
58. Wang J, Steinbacher S, Augustin M, Schreiner P, Epstein D, Mulvihill MJ and Crew AP. (2010) The crystal structure of a constitutively active mutant RON kinase suggests an intramolecular autophosphorylation hypothesis. *Biochemistry* **49**: 7972-4 [PMID:20726546]
59. Wang X, Le P, Liang C, Chan J, Kiewlich D, Miller T, Harris D, Sun L, Rice A and Vasile S *et al.*. (2003) Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. *Mol Cancer Ther* **2**: 1085-92 [PMID:14617781]

60. Weinberg LR, Albom MS, Angeles TS, Husten J, Lisko JG, McHugh RJ, Milkiewicz KL, Murthy S, Ott GR and Theroff JP *et al.*. (2011) Fused bicyclic derivatives of 2,4-diaminopyrimidine as c-Met inhibitors. *Bioorg Med Chem Lett* **21**: 164-7 [PMID:21123062]
61. Wodicka LM, Ciceri P, Davis MI, Hunt JP, Floyd M, Salerno S, Hua XH, Ford JM, Armstrong RC and Zarrinkar PP *et al.*. (2010) Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. *Chem Biol* **17**: 1241-9 [PMID:21095574]
62. Xi N. (2015) Substituted quinoline compounds and methods of use Patent number: US9133162B2. Assignee: Sunshine Lake Pharma Co Ltd, Calitor Sciences LLC. Priority date: 28/02/2011. Publication date: 15/09/2015.
63. Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, Qian F, Chu F, Bentzien F and Cancilla B *et al.*. (2011) Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. *Mol Cancer Ther* **10**: 2298-308 [PMID:21926191]
64. Yan SB, Peek VL, Ajamie R, Buchanan SG, Graff JR, Heidler SA, Hui YH, Huss KL, Konicek BW and Manro JR *et al.*. (2013) LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models. *Invest New Drugs* **31**: 833-44 [PMID:23275061]
65. You WK, Sennino B, Williamson CW, Falcón B, Hashizume H, Yao LC, Aftab DT and McDonald DM. (2011) VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. *Cancer Res* **71**: 4758-68 [PMID:21613405]
66. Zhao J, Fang L, Zhang X, Liang Y and Gou S. (2016) Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors. *Bioorg Med Chem* **24**: 3483-93 [PMID:27288183]